Clinical outcomes of patients receiving oral vonoprazan therapy vs. intravenous and oral proton pump inhibitor therapy after endoscopic submucosal dissection for gastric neoplasms: a prospective observational study

Clinical outcomes of patients receiving oral vonoprazan therapy vs. intravenous and oral proton pump inhibitor therapy after endoscopic submucosal dissection for gastric neoplasms: a prospective observational study - Clinical outcomes of patients receiving oral vonoprazan therapy after endoscopic gastric submucosal dissection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048996

Enrollment

270

Registered

2022-09-22

Start date

2022-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients indicated for endoscopic submucosal dissection according to the guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition)

Exclusion criteria

Exclusion criteria: Cases of preoperatively suspected invasive cancer deeper than the submucosa Cases of intraoperative perforation Pregnant or lactating women History of allergy to vonoprazan Cases deemed unsuitable for this study by the researchers

Design outcomes

Primary

Measure	Time frame
Postoperative bleeding rate	—

Secondary

Measure	Time frame
Ulcer healing rate(8 weeks +- 1 week after endoscopic submucosal dissection)and cost savings	—

Countries

Japan

Contacts

Public ContactDaisuke Miyaoka

Kurashiki Central Hospital Gastroenterology and Hepatology

miya98120@gmail.com+81864220210

Outcome results